WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 584431
Description: XY 018 is a RORγ antagonist that suppresses androgen receptor expression in prostate cancer cell lines and inhibits growth of tumors in androgen receptor-positive xenograft models.
MedKoo Cat#: 584431
Name: XY 018
Chemical Formula: C23H15F7N2O4
Exact Mass: 516.092
Molecular Weight: 516.3718
Elemental Analysis: C, 53.50; H, 2.93; F, 25.75; N, 5.43; O, 12.39
Synonym: XY 018; XY018; XY-018
IUPAC/Chemical Name: N-[2'-Fluoro-4'-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl][1,1'biphenyl]-4-yl]-2-nitrobenzeneacetamide
InChi Key: MNVXADPCMINSEC-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H15F7N2O4/c24-18-12-15(21(34,22(25,26)27)23(28,29)30)7-10-17(18)13-5-8-16(9-6-13)31-20(33)11-14-3-1-2-4-19(14)32(35)36/h1-10,12,34H,11H2,(H,31,33)
SMILES Code: O=C(NC1=CC=C(C2=CC=C(C(C(F)(F)F)(O)C(F)(F)F)C=C2F)C=C1)CC3=CC=CC=C3[N+]([O-])=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.09.01
The following data is based on the product molecular weight 516.3718 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
Wang et al (2016) ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat.Med. 22 488 PMID: 27019329
Ndagi et al (2016) Re-emergence of an orphan therapeutic target for the treatment of resistant prostate cancer - a through conformational and binding analysis for RORγ protein. J.Biomol.Struct.Dyn. 36 1